Non-interventional, Long-term Follow-up of Subjects Who Completed ApoGraft-01 Study

Last updated: November 24, 2019
Sponsor: Cellect Biotechnology
Overall Status: Active - Recruiting

Phase

N/A

Condition

Lymphoma

Acute Myelogenous Leukemia (Aml)

Leukemia (Pediatric)

Treatment

N/A

Clinical Study ID

NCT03260101
ApoGraft01 FU
  • Ages 18-70
  • All Genders

Study Summary

This is a non-interventional, long-term follow-up study in subjects who received ApoGraft in study ApoGraft-01. Up to 12 subjects who completed ApoGraft-01 study will be offered to participate in this follow-up study.

Subjects who completed ApoGraft-01 study and have signed informed consent for this follow-up study will be eligible to enroll. Subject will attend in-clinic visits up to 2 years post transplantation, and will undergo the following evaluations: acute and chronic graft versus host disease (GvHD) assessments, survival status (overall, relapse-free), disease status (disease relapse/recurrence), physical examination, safety laboratory and concomitant medication use.

Eligibility Criteria

Inclusion

Inclusion Criteria:

  1. Subjects who completed study ApoGraft-01 through 180 days (6 months) post-transplantation

  2. Ability to comply with the requirements of the study.

  3. Signed written informed consent

Study Design

Total Participants: 12
Study Start date:
June 10, 2018
Estimated Completion Date:
December 31, 2021

Connect with a study center

  • Rambam Medical Center

    Haifa,
    Israel

    Active - Recruiting

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.